Physician profile
Edwin Calderon
NPI 1437350873
$13,765.49
in general payments reported to CMS, 2019-2025
25 companies · $4,009 in 2025
The $4,009 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,937 · 2022: $1,861 · 2023: $2,973 · 2024: $2,985 · 2025: $4,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,467 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,467.17 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,910.80 | 2021-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $2,219.63 | 2021-2025 | Biktarvy, Descovy, Veklury |
| Janssen Biotech, INC. | $1,474.55 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $1,425.50 | 2021-2025 | Egrifta, Trogarzo |
| Merck Sharp & Dohme LLC | $850.81 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Emd Serono, INC. | $530.80 | 2021-2025 | Serostim |
| Janssen Scientific Affairs, LLC | $517.85 | 2021-2023 | Symtuza, Xarelto |
| Janssen Products, LP | $310.24 | 2021-2023 | Symtuza |
| Abbvie INC. | $255.24 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $241.93 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $207.02 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Bausch Health US, LLC | $180.99 | 2024-2025 | Wellbutrin, Aplenzin |
| Antares Pharma, INC. | $86.80 | 2024-2025 | Xyosted |
| Exact Sciences Corporation | $82.64 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.95 | 2021-2024 | Trulance, Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $69.77 | 2024-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $52.82 | 2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $48.39 | 2025 | Nuzyra |
| Octapharma USA, INC. | $47.10 | 2021-2022 | |
| Napo Pharmaceuticals INC | $46.17 | 2024-2025 | Mytesi |
| Halozyme INC | $41.38 | 2023 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.71 | 2021 | |
| Hologic Sales and Service, LLC | $22.79 | 2025 | Aptima |
| Verity Pharmaceuticals INC. | $14.13 | 2025 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.